Associated Papers
The Clinicopathological Correlation of KRAS Mutation and PTEN Expression Status in Primary and Metastatic Colorectal Carcinoma.
Hassan RT et al.
Cureus, 2024
MicroRNA-708 emerges as a potential candidate to target undruggable NRAS.
Pang JM et al.
Plos One, 2023
Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers.
Cekani E et al.
Cancers, 2022
Expanding mutational spectrum of HRAS by a patient with Schimmelpenning-Feuerstein-Mims syndrome.
Luo Q et al.
The Journal of Dermatology, 2021
BRAF and NRAS Locus-Specific Variants Have Different Outcomes on Survival to Colorectal Cancer.
Summers MG et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2017
Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma.
Zou M et al.
Thyroid : Official Journal of the American Thyroid Association, 2014
BRAF exon 15 T1799A mutation is common in melanocytic nevi, but less prevalent in cutaneous malignant melanoma, in Chinese Han.
Qi RQ et al.
The Journal of Investigative Dermatology, 2011
Coexisting NRAS and BRAF mutations in primary familial melanomas with specific CDKN2A germline alterations.
Jovanovic B et al.
The Journal of Investigative Dermatology, 2010
Select a paper to view details